Plan B
This article was originally published in The Tan Sheet
Executive Summary
Label comprehension studies for emergency contraceptives continue with mall intercept interviews slated to begin June 5. Changes were made to label after initial study phase, during which labels were shown to interviewees, Women's Capital Corp. says. Following analysis of mall intercept results, WCC will consult with FDA to develop label for actual use study in preparation for Rx-to-OTC switch NDA. Also, nonprescription sales of British analogue, Schering Health Care's Levonelle, under threat as Society for the Protection of Unborn Children secures UK High Court review June 12. Sales of Levonelle, which became available through pharmacists in January, have increased 2%-5% monthly, with one-quarter of total sales coming from non-Rx users, Schering says
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning